| Active substance | Pegcetacoplan |
| Holder | Swedish Orphan Biovitrum AB (publ) |
| Status | Running |
| Indication | Treatment of primary immune complex and C3-mediated glomerulopathy |
| Public documents | Approbation |
| Information for the patient | |
| Last update | 29/05/2026 |
Aspaveli
Last updated on